View Carpenter Technology Corporation (CRS) current and estimated P/E ratio data provided by Seeking Alpha.

The researchers found that itacitinib resulted in low CRS grades; 22%, 78%, and 0% of patients had grades 0, 1, and 2 to 5, respectively. (HealthDay News) — For patients with haploidentical ...

The researchers found that itacitinib resulted in low CRS grades; 22, 78, and 0 percent of patients had grades 0, 1, and 2 to 5, respectively. No cases of primary graft failure were reported.

Cytokine release syndrome (CRS) of any grade occurred in 39.2% of patients: 51% in the epcoritamab group and 28.6% in the glofitamab group. Grade ≥3 CRS occurred in 4.3% of patients, who were ...